Janssen Pharmaceutica Articles
US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients
7 November 2011
Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C
21 September 2011
Janssen Biotech gets FDA delay for new Simponi indication
12 September 2011
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
Janssen/J&J’s abiraterone significantly improved overall survival for advanced prostate cancer patients; but how to use it?
12 October 2010
Galapagos in deal with Johnson & Johnson unit for oncology target in 33.5 million-euro deal; US FDA delays J&J’s tapentadol ER
5 October 2010
Merck & Co returns rights to HGF antibody candidate to AVEO Pharma and Caeylx to Johnson & Johnson
1 October 2010
Vectura boosted by deal with GSK worth over $30 million upfront plus royalties; J&J unit buys rights to Acuform technology
6 August 2010
Showing 1-20 of 20 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
